Allergan to acquire Motus Therapeutics after successful drug trial: 5 things to know


Allergan is in the midst of acquiring Motus Therapeutics, a subsidiary of Rhythm Holding Company, after its relamorelin prescription achieved top line results in a phase 2b clinical trial.

Here's what you should know.

1. The prescription is used to treat gastroparesis in patients with type 1 and type 2 diabetes.

2. The trial evaluated the effects of relamorelin on key signs and symptoms of gastroparesis.

3. The trial was performed in a randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of dosing requirements.

4. Relamorelin was found to be safe and well-tolerated. There were some dose-related adverse events associated with it including the worsening of glycemic control in some patients.

5. Allergan will pay $200 million to Rhythm Holdings at the deal's closing. Rhythm will also receive a contingent payment over the commercial sale of relamorelin.

More articles on GI/endoscopy:
Nonalcoholic fatty liver disease associated with $103B in annual medical costs: 3 study insights
AGA launches patient education platform for IBD, pregnancy concerns: 3 notes
GI leader to know: Dr. R. David Shepard of Florida Medical Clinic


© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers